{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:51:38Z","timestamp":1776091898306,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.anai.2019.11.018","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T20:22:53Z","timestamp":1574713373000},"page":"219-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Future therapies for eosinophilic gastrointestinal disorders"],"prefix":"10.1016","volume":"124","author":[{"given":"Robert D.","family":"Pesek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.11.018_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MPG.0000000000002040","article-title":"Nonesophageal eosinophilic gastrointestinal disorders: clinical care and future directions","volume":"67","author":"Naramore","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.anai.2019.11.018_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.anai.2019.11.018_bib3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jgh.13281","article-title":"Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled trials","volume":"31","author":"Murali","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2019.11.018_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2014.07.034","article-title":"Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients","volume":"13","author":"Wolf","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2019.11.018_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/all.12846","article-title":"Eosinophilic esophagitis is characterized by a non-IgE mediated food hypersensitivity","volume":"71","author":"Simon","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.11.018_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s10620-018-4928-4","article-title":"Efficacy of atopy patch testing in directed dietary therapy of eosinophilic esophagitis: a pilot study","volume":"63","author":"Eckmann","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.anai.2019.11.018_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s10620-018-5045-0","article-title":"Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis","volume":"63","author":"Wang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.anai.2019.11.018_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O'Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2010.10.039","article-title":"A\u00a0striking local esophageal cytokine expression profile in eosinophilic esophagitis","volume":"127","author":"Blanchard","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1067\/mai.2001.119917","article-title":"Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response","volume":"108","author":"Straumann","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2019.11.018_bib12","article-title":"Preferential secretion of thymic stromal lymphopoietin (TSLP) by terminally differentiated esophageal epithelial cells: relevance to eosinophilic esophagitis (EoE)","volume":"18","author":"Chandramouleeswaran","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.anai.2019.11.018_bib13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2007.10.024","article-title":"IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids","volume":"120","author":"Blanchard","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPG.0b013e318043c097","article-title":"Interplay of adaptive th2 immunity with eotaxin-3\/C-C chemokine receptor 3 in eosinophilic esophagitis","volume":"45","author":"Bullock","year":"2007","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.anai.2019.11.018_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MPG.0b013e318228cee6","article-title":"Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children","volume":"53","author":"Subbarao","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.anai.2019.11.018_bib16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/apt.13141","article-title":"Basophil infiltration in eosinophilic esophagitis and proton pump inhibitor-responsive oesopheal eosinophilia","volume":"41","author":"Iwakura","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.11.018_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaci.2010.08.050","article-title":"Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta1, and increase esophageal smooth muscle contraction","volume":"126","author":"Aceves","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/his.13653","article-title":"Eosinophilic oesophagitis: relevance of mast cell infiltration","volume":"73","author":"Strasser","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.anai.2019.11.018_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/2050640617732643","article-title":"Genetic variations in the TLR3 locus are associated with eosinophilic esophagitis","volume":"6","author":"Avila-Castellano","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.anai.2019.11.018_bib20","first-page":"594","article-title":"Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy","volume":"3","author":"Johnsson","year":"2011","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.anai.2019.11.018_bib21","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1398-9995.2008.01709.x","article-title":"Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils","volume":"63","author":"Zimmermann","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.11.018_bib23","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.4049\/jimmunol.0801421","article-title":"Anti-Siglec-F antibody reduces allergen-induced airway eosinophilic inflammation and airway remodeling","volume":"183","author":"Song","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2222.2006.02456.x","article-title":"The alpha4beta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine","volume":"36","author":"Brandt","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2019.11.018_bib25","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/mi.2016.120","article-title":"Cadherin 26 is an alpha integrin-binding epithelial receptor regulated during allergic inflammation","volume":"10","author":"Caldwell","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MPG.0000000000001419","article-title":"Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment","volume":"65","author":"Politi","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.anai.2019.11.018_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jaci.2016.09.027","article-title":"Calpain-14 and its association with eosinophilic esophagitis","volume":"139","author":"Litosh","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9736","article-title":"The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses","volume":"10","author":"Azouz","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anai.2019.11.018_bib29","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mi.2013.90","article-title":"Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis","volume":"7","author":"Sherrill","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2016.02.028","article-title":"TGF-beta1 induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis","volume":"138","author":"Rawson","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/j.gastro.2014.01.051","article-title":"T-helper 2 cytokines, transforming growth factor beta1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis","volume":"146","author":"Rieder","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib32","author":"Hirano"},{"key":"10.1016\/j.anai.2019.11.018_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.anai.2019.11.018_bib37","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib39","doi-asserted-by":"crossref","first-page":"AB234","DOI":"10.1016\/j.jaci.2015.12.949","article-title":"Long-term safety and efficacy of reslizumab in children and adolescents with eosinophilic esophagitis: a review of 477 doses in 12 children over 7 years","volume":"137","author":"Markowitz","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib40","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.11.018_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast-cell associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.11.018_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clim.2008.11.009","article-title":"Anti-siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model","volume":"131","author":"Song","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPG.0b013e3182182ff8","article-title":"Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis","volume":"53","author":"Rubeinstein","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.anai.2019.11.018_bib44","first-page":"S36","article-title":"Efficacy and safety of AK002 in adult patients with active eosinophilic gastritis and\/or eosinophilic gastroenteritis: primary results from a randomized, double-blind, placebo-controlled phase 2 trial (ENIGMA study)","volume":"114","author":"Dellon","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.anai.2019.11.018_bib45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel disease","volume":"330","author":"Soler","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2019.11.018_bib46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41395-018-0145-1","article-title":"The anti-alpha4beta7 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates eosinophilic esophagitis: a novel clinical observation","volume":"113","author":"Nhu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.anai.2019.11.018_bib47","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.cgh.2018.03.024","article-title":"Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2019.11.018_bib48","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s10620-019-05617-3","article-title":"Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab","volume":"64","author":"Grandinetti","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.anai.2019.11.018_bib49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2007.06.015","article-title":"Anti-IgE treatment of eosinophil associated gastrointestinal disorders","volume":"120","author":"Foroughi","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2019.11.018_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113483","article-title":"A\u00a0pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2019.11.018_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2468-1253(18)30005-0","article-title":"Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the esophagus","volume":"3","author":"Walker","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2019.11.018_bib53","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.14309\/01.ajg.0000590932.88962.0b","article-title":"Efficacy of budesonide oral suspension for eosinophilic esophagitis in adolescents and adults: results from a phase 3, randomized, placebo-controlled trial","volume":"114","author":"Hirano","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.anai.2019.11.018_bib54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A\u00a0randomized, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic esophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.anai.2019.11.018_bib55","article-title":"Safety and efficacy of 4 dosage regimens of APT-1011: results from a phase 2b randomized double blind placebo-controlled trial to select the best dosage regimen for further development","volume":"7","author":"Dellon","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.anai.2019.11.018_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.12096","article-title":"Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis","volume":"68","author":"Straumann","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.11.018_bib57","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2010.12.1118","article-title":"Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy","volume":"127","author":"Hsu Blatman","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jaci.2014.07.026","article-title":"Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome","volume":"134","author":"Caldwell","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib59","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cells and IL-9 cells in pediatric eosinophilic esophagitis","volume":"131","author":"Otani","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib60","unstructured":"Youngblood BA, Brock EC, Leung J, et\u00a0al. Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. In press."},{"key":"10.1016\/j.anai.2019.11.018_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2012.10.057","article-title":"Eosinophilic gastrointestinal disease suggestive of pathogenesis-related class 10 (PR-10) protein allergy resolved after immunotherapy","volume":"131","author":"De Swert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.anai.2017.06.006","article-title":"Effects of allergen sensitization on response to therapy in children with eosinophilic esophagitis","volume":"119","author":"Pesek","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib63","article-title":"Recurrence of eosinophilic oesophagitis with subcutaneous grass pollen immunotherapy","volume":"15","author":"Wells","year":"2018","journal-title":"BMJ Case Rep. March"},{"key":"10.1016\/j.anai.2019.11.018_bib64","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.anai.2019.02.022","article-title":"Subcutaneous immunotherapy in patients with eosinophilic esophagitis","volume":"122","author":"Robey","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.11.018_bib65","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/cea.13037","article-title":"Treatment of gastric eosinophilic by epicutaneous immunotherapy in piglets sensitized to peanuts","volume":"47","author":"Mondoulet","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2019.11.018_bib66","doi-asserted-by":"crossref","unstructured":"Spergel JM, Elci OU, Muir AM, et\u00a0al. Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis [published online May 14, 2019]. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.014.","DOI":"10.1016\/j.cgh.2019.05.014"},{"key":"10.1016\/j.anai.2019.11.018_bib67","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.anai.2018.07.030","article-title":"Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab","volume":"121","author":"Han","year":"2018","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619314486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619314486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:23:14Z","timestamp":1761052994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619314486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1081120619314486"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.11.018","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future therapies for eosinophilic gastrointestinal disorders","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}